Alimta now approved for lung cancer

September 29th, 2008 by Wendi Lewis

Alimta, a medication manufactured by Eli Lilly & Co., which has been used for some time now in the treatment of malignant mesothelioma, has recently been approved as a first-line treatment for lung cancer.

The Food and Drug Administration (FDA) announced today that the drug can be used as a first-line treatment for advanced and metastasized non-small cell lung cancer, according to CNNMoney.com. According to the report, the manufacturer said Alimta was approved previously as a secondary treatment for non-small cell lung cancer, following chemotherapy, as well as a treatment for malignant mesothelioma, which affects the lining of the lungs.

Mesothelioma is caused by exposure to asbestos.

The new approval authorizes Alimta as a treatment for the most common form of lung cancer in combination with a standard chemotherapy drug, cisplatin, the report says.

Related posts:

  1. Mesothelioma Drug Fails Trial
  2. Mesothelioma drug maker Alfacell looks for buyer
  3. Clinical trial for pleural mesothelioma
  4. BBC report estimates 100,000 mesothelioma deaths possible

Tags: , ,

This entry was posted on Monday, September 29th, 2008 at 11:23 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

 

Trackbacks

(Trackback URL)

close Reblog this comment
Powered by Disqus · Learn more
blog comments powered by Disqus

Comments are moderated and generally will be posted if they are on-topic and not abusive.

« Study explores genetic link to asbestos disease
Mesothelioma drug maker Alfacell looks for buyer »